Loading...
•
Dec 31, 2024
Nano-X Q4 2024 Earnings Report
Nanox reported Q4 2024 results with a modest revenue increase but continued operating losses.
Key Takeaways
Nanox generated $3.0 million in revenue for Q4 2024, up from $2.4 million in the prior year period. Despite revenue growth, the company posted a net loss of $14.1 million and an operating loss of $15.0 million. The non-GAAP EPS stood at -$0.17. Teleradiology services accounted for most of the revenue.
Generated $3.0 million in Q4 revenue, up from $2.4 million YoY.
Posted a net loss of $14.1 million and an operating loss of $15.0 million.
Teleradiology services contributed $2.8 million in revenue with improved gross margins.
Cash and cash equivalents totaled $39.3 million as of December 31, 2024.
Nano-X
Nano-X
Nano-X Revenue by Segment
Revenue by Segment
Teleradiology Revenue
CapyFin.comImaging Products Revenue
CapyFin.comAI Solutions Revenue
CapyFin.com Forward Guidance
Nanox plans to build on its regulatory milestones and expand commercialization in the US and EU, with particular emphasis on its ARC system and AI product line.
Positive Outlook
- FDA clearance of Nanox.ARC for general use achieved in December 2024.
- CE mark received in EU for Nanox.ARC in February 2025.
- New partnerships with distributors in Romania and Greece to support EU expansion.
- Signed two new AI customers in Q1 2025, including Ezra AI.
- Entered 2025 with a growing portfolio of technologies poised for commercialization.
Challenges Ahead
- Continued operating and net losses.
- Gross margins remain negative on a GAAP basis.
- Revenue from imaging systems and AI remains minimal.
- Legal and administrative expenses increased significantly.
- High cash burn rate from operating activities ($36.6M in Q4).
Revenue & Expenses
Visualization of income flow from segment revenue to net income